Article

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative Review

2025-06-18

Abstract excerpt

The treatment landscape for EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) has evolved significantly with multiple combination regimens demonstrating superiority over single agent Osimertinib over the past two years. Recent trials such as FLAURA2 and MARIPOSA have explored intensified frontline regimens with FLAURA2 demonstrating improvement in PFS with addition of chemotherapy to Osimertinib and MARI...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 54f478f8-ea32-5ea5-9f72-7bdd14e495a5
DOI: 10.20944/preprints202506.1520.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewDOI 10.20944/preprints202506.1520.v1Read

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read

Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.Semantic proximity Read

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read

Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Semantic proximity Read

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinionSemantic proximity Read

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read

New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.Semantic proximity Read

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read